NU

Nuvation Bio IncNYSE NUVB Stock Report

Last reporting period 30 Sep, 2024

Updated 13 Nov, 2024

Last price

Market cap $B

0.66

Micro

Exchange

XNYS - New York Stock Exchange, Inc

NUVB Stock Analysis

NU

Uncovered

Nuvation Bio Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-44/100

Low score

Market cap $B

0.66

Dividend yield

Shares outstanding

218.8 B

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in San Francisco, California and currently employs 53 full-time employees. The company went IPO on 2020-07-01. The firm is engaged in developing differentiated and novel therapeutic candidates focused on treating patients with cancer. The firm is advancing six wholly owned compounds that have resulted from drug discovery and development programs, which include NUV-422 a cyclin-dependent kinase (CDK) inhibitor, NUV-868 a bromodomain and extra terminal (BET) inhibitor, NUV-569 a Wee1 inhibitor, an A2A adenosine receptor inhibitor program, and a drug-drug conjugate (DDC) platform. Its lead product candidate, NUV-422, is a selective small molecule inhibitor of CDK 2, 4 and 6. Its second product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. The company is developing, including NUV-569, NUV-569 is a differentiated oral small molecule selective inhibitor of Wee1 kinase, an important regulator of deoxyribonucleic acid (DNA) damage repair. Its subsidiaries include Nuvation Holdings, LLC and RePharmation Ltd.

View Section: Eyestock Rating